Abstract
Non-invasive optical imaging tools for early detecting anti-tumor immune responses are crucial for precision cancer immunotherapy. However, current probes often suffer from low imaging depth, single imaging channel, and inadequate quantification, hindering their in vivo applications. Here we develop a rare-earth-based NIR-II fluorescence ratiometric nanoprobe (DCGA) for in vivo real-time, precise, and non-invasive visualization of granzyme B (GzmB) activity, a key effector in T cell-mediated antitumor immunity, for early prediction of immunotherapy efficacy. The Nd/Er co-doped DCGA nanoprobe features NIR-II dual-emission ratiometric detection with self-calibrated target response signals, addressing challenges like uneven probe distribution and nonspecific signal interference. In vivo NIR-II ratiometric imaging reveals that GzmB activity well correlates with cytotoxic T cell responses and tumor growth, and can effectively distinguish responders from non-responders in both Hepa 1-6 tumor xenograft models and patient-derived xenograft models. Our DCGA probe shows promise for dynamic, real-time, non-invasive molecular imaging of T cell activation in deep tissues, offering effective support for tumor immunotherapy studies, precision medicine, and personalized diagnostics.
Addressing the Monitoring Gap in Immunotherapy
Immunotherapy has transformed oncology, yet it faces a significant challenge in clinical monitoring. Currently, therapeutic success is often only measurable weeks or months after treatment initiation through changes in tumor volume. Tissue biopsies, while informative, are invasive and provide limited temporal snapshots. Blood-based cytokine assays lack the spatial resolution necessary to understand the local tumor microenvironment. Optical imaging offers a non-invasive alternative, but standard fluorescent probes are limited by high background autofluorescence and poor tissue penetration. Furthermore, intensity-based probes are prone to false readings due to variations in probe concentration or tissue depth.
Design and Mechanism of the DCGA Nanoprobe
To overcome these limitations, researchers developed DCGA (DCNPs@GzmB-A1094), a ratiometric nanoprobe operating in the near-infrared-II (NIR-II) window (1000–1700 nm). This spectral region allows for deep tissue imaging with minimal scattering.
The probe utilizes rare-earth-doped down-conversion nanoparticles (DCNPs) as a core, providing two distinct emission signals: 1060 nm (from Neodymium) and 1525 nm (from Erbium). A NIR dye (A1094) is conjugated to the nanoparticle surface via a peptide linker specifically cleavable by Granzyme B (GzmB), a protease released by activated cytotoxic T cells to induce cancer cell apoptosis.
In its native state, the A1094 dye quenches the 1060 nm signal through Förster Resonance Energy Transfer (FRET). Upon exposure to GzmB in the tumor microenvironment, the peptide linker is cleaved, releasing the dye and restoring the 1060 nm fluorescence. The 1525 nm signal remains unaffected, serving as an internal reference for ratiometric quantification ($F_{1060}/F_{1525}$), which compensates for variations in probe distribution and tissue thickness.
Experimental Validation and Key Results
The DCGA probe was validated across multiple scales, including activated CD8+ T cells, various cancer cell lines, and syngeneic tumor-bearing mice. Key findings include:
- High Sensitivity and Specificity: The probe demonstrated a detection limit for GzmB of 41.6 nM and a 5.1-fold increase in the fluorescence ratio upon enzymatic activation.
- Early Prediction of Efficacy: In mouse models, the NIR-II ratiometric signal at Day 10 post-treatment showed a strong negative correlation ($r = -0.9239$) with the final tumor volume at Day 22. This allowed for the identification of treatment responders nearly two weeks before physical tumor shrinkage was detectable.
- Clinical Relevance: The probe successfully distinguished between responders and non-responders in Patient-Derived Xenograft (PDX) models using tissue from hepatocellular carcinoma patients, highlighting its potential for clinical translation.
Technical Advantages and Future Directions
A critical advantage of the DCGA probe is its superior photostability compared to traditional organic dyes. While organic dyes like IR1061 degrade rapidly under continuous laser irradiation, the lanthanide-doped DCNPs maintain stable signal intensity, facilitating prolonged real-time monitoring.
Despite these promising results, several areas for future research remain. The long-term metabolic fate and biocompatibility of rare-earth nanoparticles in humans must be rigorously evaluated. Additionally, while GzmB is a robust biomarker, future iterations could incorporate multiplexed sensing to track multiple immune checkpoints simultaneously. Finally, the clinical adoption of this technology will require the broader availability of specialized NIR-II imaging instrumentation, such as InGaAs cameras.
In conclusion, the DCGA nanoprobe represents a significant step toward precision immunotherapy, enabling real-time, non-invasive visualization of the molecular interactions that define therapeutic success.
Summary updated